Arrowhead Pharmaceuticals Files Quarterly 10-Q Report with SEC
The RNA interference therapeutics company submitted its quarterly regulatory filing as investor attention turns to upcoming cardiology conference presentations.
Regulatory Filing Submitted
Arrowhead Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 4, according to SEC EDGAR records. The Pasadena-based biotechnology company, which specializes in RNA interference therapeutics, maintains a market capitalization of approximately $13 billion with shares last closing at $89.59.
The 10-Q filing provides investors with the company's unaudited financial statements and a discussion of its financial condition and results of operations for the quarter.
Upcoming Industry Presentations
Arrowhead is scheduled to present at the European Society of Cardiology (ESC) Congress 2026, which runs from August 28 through August 31, according to MarginX data. The company has a specific presentation slot on August 30 at 5:30 PM, followed by a special call on August 31. The ESC Congress represents one of the world's largest gatherings of cardiovascular professionals, suggesting the company may share data related to its cardiovascular therapeutic pipeline.
Recent Insider Activity
MarginX data shows recent insider transactions at the company. Matthew Gregory Cohen received an award of 11,882 shares, while Hongbo Lu sold 2,970 shares and James C. Hamilton sold 10,000 shares. Such transactions are routine disclosures required of company insiders and may reflect pre-planned trading arrangements or personal financial planning rather than views on company prospects.
Broader Context
The filing comes as biotechnology companies face an evolving macroeconomic environment, with the Federal Reserve's next rate decision and projections scheduled for September 16, according to MarginX data. Interest rate policy has historically influenced valuations in growth-oriented sectors like biotechnology, which often require significant capital investment in research and development ahead of product commercialization.
Arrowhead's 10-Q filing is available through the SEC's EDGAR database for investors seeking detailed financial information.
This article was generated by MarginX from public news on 2026-08-04. It is not investment advice.